Delfi Diagnostics is a pioneering developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection.
Delfi's mission is to develop an innovative blood test for detection of cancer when it is most curable.
Delfi Diagnostics was founded in 2019 by Victor Velculescu. The company is headquartered in Baltimore, Maryland.
Delfi's technology leverages advances in machine learning and recent discoveries in the genome-wide fragmentation profiles of cell free DNA to create a novel approach to detecting evidence of a tumor from a blood sample, while also pinpointing the tumor's location in the body.
Delfi analyzes cell-free DNA fragments across the entire genome. This allows for a single, low-cost, and straightforward lab process for any test developed on the platform. When combined with breakthroughs in machine learning, the Delfi platform can deliver high-performing results for multiple applications.
Delfi is currently validating the technology for early detection of lung and other cancers in a 15,000-person prospective trial called CASCADE-LUNG, and is working with multiple research institutions to develop additional applications including screening for other cancer types, multi-cancer early detection, and treatment monitoring.
Delfi is backed by OrbiMed, DFJ Growth, Menlo Ventures, Eli Lilly and Company, Samsara Biocapital, Point72, Illumina Ventures, Foresite Capital, Northpond Ventures, AV8 Ventures, Windham Venture Partners, Brown Advisory, and others. The company raised $225M in Series B round on Jul 18, 2022. This brings Delfi's total funding to $330.5M to date.